$CARA Begins Phase 3 Program

Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative…

$CARA Issued Additional U.S. Patent

Cara Therapeutics Issued Additional U.S. Patent Covering the Expanded Use of Kappa…

$CARA Webcast Presentation at 17th Annual BIO CEO & Investor Conference

Cara Therapeutics to Webcast Presentation at 17th Annual BIO CEO & Investor…

$CARA Announces NASDAQ Addition

Cara Therapeutics Announces Addition to the NASDAQ Biotechnology Index SHELTON, Conn., Dec.…